hbsag seroclearance in na-treated patients · hbv-dna (virions) hbv replication. q. hbsag virions +...

31
HBsAg seroclearance in NA-treated patients International Symposium on Hepatology 2017 & 30th Annual Scientific Meeting Dr Grace Lai-Hung Wong MBChB (Hons, CUHK), MD (CUHK), MRCP, FHKCP, FHKAM (Medicine) Professor, Institute of Digestive Disease The Chinese University of Hong Kong HKASLD HKASLD HKASLD HKASLD HKASLD HKASLD HKASLD HKASLD

Upload: others

Post on 18-Oct-2020

7 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: HBsAg seroclearance in NA-treated patients · HBV-DNA (virions) HBV replication. q. HBsAg virions + defective particles. cccDNA transcription/ mRNA translation . Chan HL et al., J

HBsAg seroclearance in NA-treated patients

International Symposium on Hepatology 2017 & 30th Annual Scientific Meeting

Dr Grace Lai-Hung WongMBChB (Hons, CUHK), MD (CUHK), MRCP, FHKCP, FHKAM (Medicine)

Professor, Institute of Digestive DiseaseThe Chinese University of Hong Kong

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

Page 2: HBsAg seroclearance in NA-treated patients · HBV-DNA (virions) HBV replication. q. HBsAg virions + defective particles. cccDNA transcription/ mRNA translation . Chan HL et al., J

Disclosures

• Advisory committee member: Gilead

• Speaker: AbbVie, Bristol-Myers Squibb, Echosens & Furui, Gilead, Janssen, Roche

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

Page 3: HBsAg seroclearance in NA-treated patients · HBV-DNA (virions) HBV replication. q. HBsAg virions + defective particles. cccDNA transcription/ mRNA translation . Chan HL et al., J

CAN CHRONIC HEPATITIS B BE CURED?

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

Page 4: HBsAg seroclearance in NA-treated patients · HBV-DNA (virions) HBV replication. q. HBsAg virions + defective particles. cccDNA transcription/ mRNA translation . Chan HL et al., J

Cure of chronic hepatitis B• Functional cure

– HBsAg seroclearance +/-seroconversion• Absolute or complete cure

– Absence of cccDNA

Liu et al.Gut 2014. Block et al.Antiviral Res 2013.

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

Page 5: HBsAg seroclearance in NA-treated patients · HBV-DNA (virions) HBV replication. q. HBsAg virions + defective particles. cccDNA transcription/ mRNA translation . Chan HL et al., J

HBV DNA vs. HBsAg

HBV-DNA(virions)

HBV replication

qHBsAgvirions + defective particles

cccDNA transcription/mRNA translation

Chan HL et al., J Hepatol. 2011;55:1121-31.

HBV replication

Serum HBV DNA: a marker of

HBV replication

Serum HBsAg: a marker of transcriptionally

active cccDNA*HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

Page 6: HBsAg seroclearance in NA-treated patients · HBV-DNA (virions) HBV replication. q. HBsAg virions + defective particles. cccDNA transcription/ mRNA translation . Chan HL et al., J

HBsAg seroclearance Treatment goal of chronic hepatitis B

APASL 2016, EASL 2017, AASLD 2016Yuen MF, et al. Gastroenterology 2008

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

Page 7: HBsAg seroclearance in NA-treated patients · HBV-DNA (virions) HBV replication. q. HBsAg virions + defective particles. cccDNA transcription/ mRNA translation . Chan HL et al., J

Benefits of HBsAg seroclearance

• p Hepatic decompensation

• p HCC

• n Survival

• p Levels of cccDNA

• As close to cure as we can expect to achieve in

chronic hepatitis B

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

Page 8: HBsAg seroclearance in NA-treated patients · HBV-DNA (virions) HBV replication. q. HBsAg virions + defective particles. cccDNA transcription/ mRNA translation . Chan HL et al., J

HBsAg seroclearance – what’s new

1. Durability of HBsAg seroclearance

2. Risk factors of HCC after HBsAg seroclearance

3. Management of CHB patients with HBsAg

seroclearance

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

Page 9: HBsAg seroclearance in NA-treated patients · HBV-DNA (virions) HBV replication. q. HBsAg virions + defective particles. cccDNA transcription/ mRNA translation . Chan HL et al., J

DURABILITY OF HBSAG SEROCLEARANCE

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

Page 10: HBsAg seroclearance in NA-treated patients · HBV-DNA (virions) HBV replication. q. HBsAg virions + defective particles. cccDNA transcription/ mRNA translation . Chan HL et al., J

Durability of HBsAg seroclearance in untreated and NA-treated patients

Yip TC, Wong GL, et al. J Hepatology 2017 (in press)HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

Page 11: HBsAg seroclearance in NA-treated patients · HBV-DNA (virions) HBV replication. q. HBsAg virions + defective particles. cccDNA transcription/ mRNA translation . Chan HL et al., J

Both spontaneous and NA-induced HBsAg seroclearance are durable

5-year cumulative rate of HBsAg seroclearance:

spontaneous 88.1%NA-induced 92.2%

log-rank test, P=0.964

Yip TC, Wong GL, et al. J Hepatology 2017 (in press)HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

Page 12: HBsAg seroclearance in NA-treated patients · HBV-DNA (virions) HBV replication. q. HBsAg virions + defective particles. cccDNA transcription/ mRNA translation . Chan HL et al., J

Presence of anti-HBs increases durability of spontaneous HBsAg seroclearance, but not NA-induced one

Yip TC, Wong GL, et al. J Hepatology 2017 (in press)

Spontaneous NA-induced

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

Page 13: HBsAg seroclearance in NA-treated patients · HBV-DNA (virions) HBV replication. q. HBsAg virions + defective particles. cccDNA transcription/ mRNA translation . Chan HL et al., J

None of patients who had received consolidation therapy for 12 months or more developed HBsAg seroreversion

Yip TC, Wong GL, et al. J Hepatology 2017 (in press)HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

Page 14: HBsAg seroclearance in NA-treated patients · HBV-DNA (virions) HBV replication. q. HBsAg virions + defective particles. cccDNA transcription/ mRNA translation . Chan HL et al., J

Summary

• NA-induced HBsAg seroclearance is as durable as that

occurs spontaneously.

• HBsAg seroconversion, i.e. the presence of anti-HBs is

not essential for maintaining HBsAg seroclearance after

NA treatment.

• Consolidation therapy for 12 months or more may

minimize the risk of HBsAg seroreversion.

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

Page 15: HBsAg seroclearance in NA-treated patients · HBV-DNA (virions) HBV replication. q. HBsAg virions + defective particles. cccDNA transcription/ mRNA translation . Chan HL et al., J

RISK FACTORS OF HCC AFTER

HBSAG SEROCLEARANCE

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

Page 16: HBsAg seroclearance in NA-treated patients · HBV-DNA (virions) HBV replication. q. HBsAg virions + defective particles. cccDNA transcription/ mRNA translation . Chan HL et al., J

HK data – 1,680 patients in ETV/TDFBaseline HBsAg level and HCC

Cirrhosis No Cirrhosis

N = 415P = 0.933

N = 1,265P = 0.08

The were a trend that baseline HBsAg level predicts HCC in non-cirrhotic patients.

Wong GL, et al. Gastroenterology 2013;144:933-44.HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

Page 17: HBsAg seroclearance in NA-treated patients · HBV-DNA (virions) HBV replication. q. HBsAg virions + defective particles. cccDNA transcription/ mRNA translation . Chan HL et al., J

HBsAg level in HCC risk score

Yang HI, et al. Clin Gastroenterol Hepatol. 2016;14:461-468.e2.HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

Page 18: HBsAg seroclearance in NA-treated patients · HBV-DNA (virions) HBV replication. q. HBsAg virions + defective particles. cccDNA transcription/ mRNA translation . Chan HL et al., J

HBsAg seroclearance in patients on NAs

Original cohort: 110 HBsAg seroclearance; 5299 controlsPropensity score matching: 93 HBsAg seroclearance; 372 controls

Kim et al. Gut 2014;63:1325Wong VW et al. Gastroenterology 2014;147:1435

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

Page 19: HBsAg seroclearance in NA-treated patients · HBV-DNA (virions) HBV replication. q. HBsAg virions + defective particles. cccDNA transcription/ mRNA translation . Chan HL et al., J

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

Page 20: HBsAg seroclearance in NA-treated patients · HBV-DNA (virions) HBV replication. q. HBsAg virions + defective particles. cccDNA transcription/ mRNA translation . Chan HL et al., J

Yip TC,……Wong GL. J Hepatology 2017 Nov;67(5):902-908.HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

Page 21: HBsAg seroclearance in NA-treated patients · HBV-DNA (virions) HBV replication. q. HBsAg virions + defective particles. cccDNA transcription/ mRNA translation . Chan HL et al., J

Age and gender on HCC development

Yip TC,……Wong GL. J Hepatology 2017 Nov;67(5):902-908.HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

Page 22: HBsAg seroclearance in NA-treated patients · HBV-DNA (virions) HBV replication. q. HBsAg virions + defective particles. cccDNA transcription/ mRNA translation . Chan HL et al., J

Cox proportional hazard model

Model Variable Univariate analysis Multivariate analysis

HR 95% CI P HR 95% CI P

1 Age>50 4.49 1.79-11.27 0.001 4.31 1.71-10.84 0.002

Male 2.59 1.30-2.15 0.007 2.47 1.24-4.91 0.01

2 Age (per yr) 1.04 1.02-1.07 <0.001 1.05 1.02-1.07 <0.001

Male 2.59 1.30-2.15 0.007 2.55 1.28-5.07 0.007

Yip TC,……Wong GL. J Hepatology 2017 Nov;67(5):902-908.HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

Page 23: HBsAg seroclearance in NA-treated patients · HBV-DNA (virions) HBV replication. q. HBsAg virions + defective particles. cccDNA transcription/ mRNA translation . Chan HL et al., J

3 risk levels of HCC after HBsAg seroclearance

Highest riskMale > 50

Intermediate riskDĂůĞ�чϱϬFemale >50

Lowest (no) risk&ĞŵĂůĞ�чϱϬ

Yip TC,……Wong GL. J Hepatology 2017 Nov;67(5):902-908.HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

Page 24: HBsAg seroclearance in NA-treated patients · HBV-DNA (virions) HBV replication. q. HBsAg virions + defective particles. cccDNA transcription/ mRNA translation . Chan HL et al., J

Summary – age and gender on HCC risk after HBsAg seroclearance

• Cumulative risk of HCC development after HBsAg

seroclearance = 1.5% in 5 years

• Age >50 years and male gender are independent risk

factors for HCC

• Male patients who clear HBsAg at age >50 years have

significant risk of HCC (2.5% in 5 years)

• Female patients who clear HBsAg before age of 50 have

very low risk of HCC (0% in 5 years)

Yip TC,……Wong GL. J Hepatology 2017 Nov;67(5):902-908.HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

Page 25: HBsAg seroclearance in NA-treated patients · HBV-DNA (virions) HBV replication. q. HBsAg virions + defective particles. cccDNA transcription/ mRNA translation . Chan HL et al., J

DM increases HCC risks Good glycemic control reduces HCC risk

Yip TC,……Wong GL. APDW 2017

DM on HCC risk after HBsAg seroclearance

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

Page 26: HBsAg seroclearance in NA-treated patients · HBV-DNA (virions) HBV replication. q. HBsAg virions + defective particles. cccDNA transcription/ mRNA translation . Chan HL et al., J

MANAGEMENT OF PATIENTS WITH

HBSAG SEROCLEARANCE

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

Page 27: HBsAg seroclearance in NA-treated patients · HBV-DNA (virions) HBV replication. q. HBsAg virions + defective particles. cccDNA transcription/ mRNA translation . Chan HL et al., J

Monitoring of patients with HBsAg seroclearance

• In general, no need further evaluation

• In case of suspicion of liver disease (e.g. elevated ALT level or

suspicion of liver cirrhosis)

– Check anti-HBc ± HBV DNA

– Exclude other liver diseases (e.g. co-infection with HCV, alcohol, NAFLD)

• If detectable HBV DNA (usually low titre)

– Yearly LFT and HBV DNA

– Fibroscan to exclude cirrhosis (esp. if age >50)

– Antiviral if HBV DNA +ve AND cirrhosis

– HCC screening not essential unless the patient is cirrhotic or had HBsAg

seroclearance in males after the age of 50HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

Page 28: HBsAg seroclearance in NA-treated patients · HBV-DNA (virions) HBV replication. q. HBsAg virions + defective particles. cccDNA transcription/ mRNA translation . Chan HL et al., J

HBsAg seroclearance – can it be occult HBV infection?

• HBsAg negative

• Detection of HBV DNA in the serum or the liver

• Anti-HBs and anti-HBc may be positive or negative

• In real life, anti-HBc is often the marker for possible occult

HBV infection

Raimondo et al. J Hepatol 2008;49:652HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

Page 29: HBsAg seroclearance in NA-treated patients · HBV-DNA (virions) HBV replication. q. HBsAg virions + defective particles. cccDNA transcription/ mRNA translation . Chan HL et al., J

Immunosuppressants and risk of reactivation of occult HBV infectionAgent Risk (%)

B cell-depleting agents (e.g. rituximab) >10

TNF-ɲ inhibitors (e.g. infliximab) 1

Tyrosine kinase inhibitors (e.g. imatinib) 1

Doxorubicin and epirubicin 1-10

Azathioprine, 6-MP, methotrexate <<1

Systemic corticosteroids

Moderate to high dose >4 weeks 1-10

Moderate to high dose <1 week <<1

Low dose >4 weeks <1

Perrillo et al. Gastroenterology 2015;148:221

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

Page 30: HBsAg seroclearance in NA-treated patients · HBV-DNA (virions) HBV replication. q. HBsAg virions + defective particles. cccDNA transcription/ mRNA translation . Chan HL et al., J

Conclusions• HBsAg seroclearance is as durable

– ~90% in 5 years

– NA-induced ~ spontaneous

• In NA-induced HBsAg seroclearance, presence of

anti-HBs does not affect durability.

• Females of age <50 would be of minimal risk of HCC

after HBsAg seroclearance.

• Good glycemic control in DM patients reduces HCC risk

after HBsAg seroclearance. HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

Page 31: HBsAg seroclearance in NA-treated patients · HBV-DNA (virions) HBV replication. q. HBsAg virions + defective particles. cccDNA transcription/ mRNA translation . Chan HL et al., J

Database team, Institute of Digestive Disease, CUHK

Thank you for your attention!

Grace Lai-Hung WongInstitute of Digestive DiseaseThe Chinese University of Hong KongE-mail: [email protected]

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD

HKASLD HKASLD